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OBJECTIVE—Type 2 diabetes accompanied by renal damage is a strong risk factor for ath-
erosclerotic events. The purpose of this study was to investigate the efﬁcacy of low-dose aspirin
therapy on primary prevention of atherosclerotic events in patients with type 2 diabetes and
coexisting renal dysfunction.
RESEARCH DESIGN AND METHODS—The Japanese Primary Prevention of Athero-
sclerosis With Aspirin for Diabetes (JPAD) trial was a prospective, randomized, open-label trial
conducted throughout Japan that enrolled 2,539 type 2 diabetic patients without a history of
atherosclerotic diseases. Patients were assignedto the aspiringroup (81 mg/day or 100 mg/day) or
the nonaspirin group and followed for a median of 4.37 years. The primary end points were ath-
eroscleroticeventsoffatalandnonfatalischemicheartdisease,stroke,andperipheralarterialdisease.
RESULTS—Theanalysisincluded2,523patientswhohadserumcreatininemeasured.In1,373
patients with baseline estimated glomerular ﬁltration rate (eGFR) 60–89 mL/min/1.73 m
2, the
incidenceofprimaryendpointswassigniﬁcantlylowerintheaspiringroupthaninthenonaspirin
group (aspirin, 30/661; nonaspirin, 55/712; hazard ratio 0.57 [95% CI 0.36–0.88]; P = 0.011).
Low-dose aspirin therapy did not reduce primary end points in patients with eGFR $90 mL/min/
1.73 m
2 (aspirin, 9/248; nonaspirin, 11/270; 0.94 [0.38–2.3]) or those with eGFR ,60 mL/min/
1.73 m
2 (aspirin, 29/342; nonaspirin, 19/290; 1.3 [0.76–2.4]). The Cox proportional hazard
model demonstrated a signiﬁcant interaction between mild renal dysfunction (eGFR 60–
89 mL/min/1.73 m
2)a n da s p i r i n( P = 0.02).
CONCLUSIONS—These results suggest a differential effect of low-dose aspirin therapy in
diabetic patients with eGFR 60–89 mL/min/1.73 m
2.
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D
iabetes is a strong risk factor for
cardiovascular (CV) events. How-
ever,theprimarypreventionstrategy
for CV events remains to be established
(1). In patients with type 2 diabetes, the
presence of coexisting renal damage is
associated with an increased incidence
of CV events (2–4). Although diabetic
nephropathyisdiagnosedbypathological
examination,thepresenceofalbuminuriais
clinically adopted as pathognomonic man-
ifestation of diabetic nephropathy.
Recently, the National Kidney Foun-
dation (5) deﬁnes chronic kidney disease
aspersistentkidneydamageofanyunder-
lying cause, as reﬂected by estimated glo-
merular ﬁltration rate (eGFR) of ,60 mL/
min/1.73 m
2 for more than 3 months.
eGFR ,60 mL/min/1.73 m
2 is the cutoff
because it has been identiﬁed as a predic-
torofCVeventsinthegeneral population
(6), in patients with diabetes (3,4), and in
patients with other CV risk factors (6,7).
Given that nearly two thirds of diabetic
patients with eGFR ,60 mL/min/1.73 m
2
have normal albuminuria (8), American
Diabetes Association (ADA) guidelines
(9) recommend that serum creatinine
should be measured at least annually and
used to calculate eGFR in all diabetic pa-
tients,regardlessofthedegreeofalbumin-
uria (8,9). Thus, to establish the primary
prevention strategy for diabetic patients
withrenaldamage,aGFR-basedapproach
might be helpful.
Low-dose aspirin therapy has previ-
ously been recommended by several key
guidelines for primary prevention of CV
events in patients with diabetes, although
with some inconsistencies (1,9). In 2010,
theADA,theAmericanHeartAssociation,
and the American College of Cardiology
Foundation convened a group of experts
to create updated recommendations for
the primary prevention strategy of low-
dose aspirin use in patients with diabetes
(1). They performed a new meta-analysis
that included two recent randomized
controlled trials of aspirin, the Japanese
Primary Prevention of Atherosclerosis
With Aspirin for Diabetes (JPAD) trial
(10), and the Prevention of Progression of
ArterialDiseasesandDiabetes(POPADAD)
trial(11).Bothtrialsenrolledonlypatients
with diabetes and neither showed any sig-
niﬁcant effect of aspirin to prevent athero-
sclerotic events.
Based on the currently available evi-
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ORIGINAL ARTICLEmodest effect on CV events, with an ab-
solute decrease in events depending on
the underlying CV disease risk. They
jointly stated the recommendation that
low-doseaspirinuseforpreventionisrea-
sonable for adults with diabetes and no
previous history of vascular disease who
are at increased CV disease risk, but not
foradultswithlowrisk.Thoseadultswith
diabetes at increased CV disease risk in-
clude most of men over age 50 years and
womenoverage60yearswhohaveoneor
more of following additional risk factors:
smoking, hypertension, dyslipidemia,
family history of premature CV disease,
and albuminuria (1). Probably because
there are sufﬁcient data concerning
eGFR, they did not mention eGFR as an
additional risk.
The aim of this study was to deter-
mine whether GFR-dependent risk strat-
iﬁcation affects the efﬁcacy of low-dose
aspirin therapy for primary prevention of
atherosclerotic events in patients with
diabetes in the JPAD trial.
RESEARCH DESIGN AND
METHODS—Theobjectivesandmeth-
ods of the JPAD trial have been described
previously (10). In brief, the JPAD trial
randomly assigned 2,539 patients with
type2diabeteswithoutanyhistoryofath-
erosclerotic diseases between the ages of
30 and 85 years to the aspirin or nonas-
pirin group. Patients in the aspirin group
were assigned to take 81 mg or 100 mg of
aspirin once daily. The dosage of aspirin
(81 mg or 100 mg) was chosen by each
physician. JPAD was a prospective, non-
blinded, randomized clinical trial; event
adjudicationwasdonebyanindependent
endpointcommitteeblindedtotreatment
assignment. Japanese Pharmaceutical Af-
fairs Law prohibits the use of placebo in
large physician-conducted studies.
The primary end point was any ath-
eroscleroticevent,whichwasacomposite
of sudden death: death from coronary,
cerebrovascular, and aortic causes; non-
fatalacutemyocardialinfarction;unstable
angina; newly developed exertional an-
gina; nonfatal ischemic and hemorrhagic
stroke; transient ischemic attack; or non-
fatalaorticandperipheralvasculardisease
(arteriosclerosis obliterans, aortic dissec-
tion, and mesenteric arterial thrombosis)
during the follow-up period. Secondary
end points were combinations of events:
atherosclerotic/ischemic (death from cor-
onary, cerebrovascular causes; nonfatal
acute myocardial infarction; unstable an-
gina, newly developed exertional angina;
nonfatal ischemic stroke; transient ische-
mic attack; or nonfatal peripheral vascu-
lar disease), structural (aortic dissection),
and hemorrhagic events (hemorrhagic
stroke). Adverse events analyzed in-
cluded gastrointestinal events and hem-
orrhagic stroke.
We performed a post hoc subgroup
analysis to analyze the relationship be-
tween renal function and atherosclerotic
events and the effect of aspirin in patients
with normal and reduced renal function;
eGFR was calculated for patients whose
serum creatinine was available. The base-
line eGFR (mL/min/1.73 m
2 of body sur-
face area) was calculated by the new
three-variable Japanese equation for GFR
(eGFR = 194 3 serum creatinine
21.094 3
age
20.287 3 0.739 [if female]) instead of
the Modiﬁcation of Diet in Renal Disease
equation, because in a Japanese popula-
tion this equation is more accurate than
the other equations when compared with
measured GFR computed from inulin
clearance (14). Those patients without
creatinine values at baseline were ex-
cluded from this analysis.
Statistical analysis
Efﬁcacy comparisons were performed
based on the time to the ﬁrst event,
according to the intention-to-treat prin-
ciple, including patients lost to follow-up
who were censored at the time of the last
visit. We ﬁrst divided all patients into
three groups based on eGFR ($90, 60–
89, ,60 mL/min/1.73 m
2), according to
the guidelines of the National Kidney
Foundation (5). We assessed the differ-
ence in baseline characteristics among
eGFR groups by t test or Wilcoxon rank
sum test for continuous variables and x
2
test for categorical variables. We evalu-
ated the effects of the baseline eGFR
groups on the cumulative incidences of
the primary end point by the Kaplan-
Meier method, and differences between
groups were assessed with the log-rank
test. We used the Cox proportional haz-
ards model to estimate hazard ratios
(HRs) and their CIs. We also assessed
the effects of aspirin on primary end
points stratiﬁed by combinations of
eGFR groups and age at baseline.
Stratiﬁed by eGFR groups, the study
population was assessed for the effects of
aspirinonatheroscleroticevents.Wedevel-
oped Cox proportional hazard models in
each stratum of eGFR groups.On the basis
of the hypothesis that mild renal dysfunc-
tion (eGFR 60–89 mL/min/1.73 m
2) has
an interaction with aspirin, we developed
a Cox proportional hazard model with
the interaction variable between aspirin
and eGFR 60–89 mL/min/1.73 m
2 vari-
able. The included variables were aspi-
rin, dummy variable for eGFR 60–89
mL/min/1.73 m
2 (relative to eGFR $90
mL/min/1.73 m
2), dummy variable for
eGFR ,60 mL/min/1.73 m
2 (relative to
eGFR $90), interaction variable be-
tween eGFR 60–89 mL/min/1.73 m
2 and
aspirin. We also developed multivariable
Cox proportional hazard models to assess
theeffectsofaspirin onprimary endpoints
adjusting for age, hypertension, dyslipide-
mia, and history of smoking to see the ro-
bustness.
Differences in adverse events, includ-
ing any hemorrhagic events and gastro-
intestinal bleeding according to eGFR,
were assessed by x
2 test or Fisher exact
test. Patients with missing values for any
selected variable were excluded from the
analyses that used the variable. All statis-
tical analyses were performed using SAS
version 9.1 (SAS Institute, Cary, NC). P
values ,0.05 were considered statisti-
cally signiﬁcant.
RESULTS—Because 16 patients were
excluded from the analysis as a result of
the lack of availability of the baseline
serum creatinine level, 2,523 of the
2,539 patients originally enrolled in the
JPAD trial were included in the current
study, as shown in Supplementary Fig. 1.
The baseline demographics by eGFR are
s h o w ni nS u p p l e m e n t a r yT a b l e1 .T h e
mean (SD) serum creatinine level at base-
line was 0.8 (0.3) mg/dL and the mean
eGFR was 74 (21) mL/min/1.73 m
2.
As shown in Table 1, there were no
signiﬁcant differences in baseline demo-
graphics between the aspirin group and
the nonaspirin group. There were also
no signiﬁcant differences in each category
ofpatientsstratiﬁedbyeGFR,exceptinthe
group with eGFR $90 mL/min/1.73 m
2
patients, who were signiﬁcantly older in
the aspirin group than in the nonaspirin
group, and in the group with eGFR 60–
89mL/min/1.73m
2,whosediastolicblood
pressure was slightly but signiﬁcantly
higherintheaspiringroupthaninthenon-
aspirin group and whose incidence of his-
tory of smoking was signiﬁcantly higher in
the aspirin group than in the nonaspirin
group.
Relation between eGFR and primary
end points
Incidence of primary end points signif-
icantly increased with declining eGFR
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Saito and Associates(P = 0.03), as shown in Supplementary
Fig. 2. The group of patients with eGFR
$90mL/min/1.73m
2wasusedastheref-
erence group in the analysis of the associ-
ation between the level of eGFR and
primary end points. The incidence of pri-
mary end points was signiﬁcantly higher
in patients with mildly reduced eGFR
60–89 mL/min/1.73 m
2 (HR 1.6 [95% CI
1.0–2.7]; P = 0.048) and in patients with
eGFR ,60 mL/min/1.73 m
2 (2.0 [1.2–
3.5]; P =0 . 0 0 6 6 ) .
Efﬁcacy of low-dose aspirin therapy
on primary and secondary end points
in diabetic patients with reduced GFR
In 1,373 patients with eGFR 60–89 mL/
min/1.73 m
2 (661 patients in the aspirin
group and 712 patients in the nonaspirin
group), a total of 85 primary end points
(any atherosclerotic event) occurred: 30 in
the aspirin group and 55 in the nonaspirin
group (HR 0.57 [95% CI 0.36–0.88]; P =
0.011) (Fig. 1B). The Cox proportional
hazard model demonstrated signiﬁcant
interaction between mild renal dysfunc-
tion (eGFR 60–89 mL/min/1.73 m
2) and
aspirin use (P =0.02).However,there was
no signiﬁcant difference in the incidence
of primary end points in patients with
eGFR $90 mL/min/1.73 m
2 (nine events
in the aspirin group and 11 events in
the nonaspirin group; 0.94 [0.38–2.3])
(Fig.1A),orthosewitheGFR,60mL/min/
1.73 m
2 (29 events in the aspirin group
and 19 in the nonaspirin group; 1.3
[0.76–2.4]) (Fig. 1C). Adjusting for age,
hypertension, dyslipidemia, and history
of smoking, low-dose aspirin signiﬁcantly
reduced primary end points in patients
with eGFR 60–89 mL/min/1.73 m
2 (0.53
[0.34–0.83]; P = 0.0052), and not in pa-
tients with eGFR $90 or ,60 mL/min/
1.73 m
2 (eGFR $90 mL/min/1.73 m
2:
0.87 [0.36–2.14]; eGFR ,60 mL/min/
1.73 m
2: 1.24 [0.69–2.23]).
The secondary end point of athero-
sclerotic/ischemic events occurred in 26
patients in the aspirin group and in 50
patients in the nonaspirin group, among
the patients with eGFR 60–89 mL/min/
1.73 m
2 (HR 0.54 [0.33–0.86]; P =
0.010) (Supplementary Table 2). The in-
cidence of atherosclerotic/ischemic events
was similar between the aspirin and non-
aspiringroupsinbothcategoriesofpatients
with eGFR of at least 90 mL/min/1.73 m
2
(1.15[0.45–2.95];P=0.76)andthosewith
eGFR ,60 mL/min/1.73 m
2 (1.29 [0.70–
2.43]; P = 0.42) (Supplementary Table 2).
In the structural and hemorrhagic events,
the beneﬁt of aspirin was not observed
in any category of patients stratiﬁed by
eGFR.
Efﬁcacy of low-dose aspirin therapy
on primary end points in subgroups
As reported previously, the incidence of
primary end points was signiﬁcantly
lower in the aspirin group than in the
nonaspirin group in the subgroup of
patients aged 65 years or older (Fig. 2)
(10). In the subgroups of patients aged
65 years or older whose eGFR was 60–
89 mL/min/1.73 m
2, low-dose aspirin
Table 1—Baseline demographics by treatment
eGFR $90 mL/min/1.73 m
2 eGFR 60–89 mL/min/1.73 m
2 eGFR ,60 mL/min/1.73 m
2
Aspirin Nonaspirin P Aspirin Nonaspirin P Aspirin Nonaspirin P
n 248 270 661 712 342 290
Age (years), mean (SD) 61 (9) 58 (10) 0.0001 65 (10) 65 (10) 0.6 68 (9) 69 (8) 0.7
Male, n (%) 127 (51) 130 (48) 0.5 386 (58) 398 (56) 0.4 184 (54) 150 (52) 0.6
Hypertension, n (%) 120 (48) 131 (49) 0.97 376 (57) 399 (56) 0.8 242 (71) 198 (68) 0.5
Dyslipidemia, n (%) 140 (56) 132 (49) 0.09 339 (51) 362 (51) 0.9 195 (57) 168 (58) 0.8
Laboratory measurements
Glycated hemoglobin (%),
mean (SD) 7.5 (1.7) 7.4 (1.4) 0.3 7.0 (1.3) 6.9 (1.2) 0.2 7.0 (1.3) 6.9 (1.1) 0.1
Serum creatinine level (mg/dL),
mean (SD) 0.5 (0.09) 0.5 (0.1) 0.2 0.7 (0.1) 0.7 (0.1) 0.8 1.1 (0.5) 1.0 (0.2) 0.2
Dipstick-positive
proteinuria, n (%) 32 (13) 35 (13) 0.96 68 (10) 72 (10) 0.9 76 (23) 63 (22) 0.9
Blood pressure (mmHg), mean (SD)
Systolic 134 (16) 134 (16) 0.6 135 (14) 134 (14) 0.07 138 (15) 136 (15) 0.1
Diastolic 77 (10) 77 (10) 0.9 77 (9) 76 (9) 0.01 77 (9) 76 (10) 0.1
Medications for diabetes, n (%)
Sulfonylurea 145 (58) 146 (54) 0.3 384 (58) 382 (54) 0.1 205 (60) 177 (61) 0.8
a-Glucosidase inhibitor 90 (36) 80 (30) 0.1 222 (34) 238 (33) 0.95 105 (31) 94 (32) 0.6
Biguanides 38 (15) 56 (21) 0.1 82 (12) 96 (13) 0.6 47 (14) 34 (12) 0.4
Insulin 42 (17) 46 (17) 0.97 87 (13) 80 (11) 0.3 36 (11) 34 (12) 0.6
Thiazolidinediones 10 (4) 23 (9) 0.04 31 (5) 31 (4) 0.8 21 (6) 11 (4) 0.2
Medication for hypertension and dyslipidemia, n (%)
Calcium channel blocker 73 (29) 75 (28) 0.7 214 (32) 239 (34) 0.6 149 (44) 123 (42) 0.8
Angiotensin receptor blocker 36 (15) 41 (15) 0.8 135 (20) 137 (19) 0.6 94 (27) 88 (30) 0.4
Angiotensin-converting
enzyme inhibitor 30 (12) 39 (14) 0.4 96 (15) 104 (15) 0.96 52 (15) 52 (18) 0.4
b-Blocker 10 (4) 14 (5) 0.5 40 (6) 49 (7) 0.5 25 (7) 24 (8) 0.7
a-Blocker 4 (1.6) 5 (1.9) 1 25 (4) 22 (3) 0.5 24 (7) 11 (4) 0.08
Statins 69 (28) 61 (23) 0.2 159 (24) 179 (25) 0.6 91 (27) 87 (30) 0.3
History of smoking, n (%) 113 (46) 109 (40) 0.2 311 (47) 282 (40) 0.005 140 (41) 100 (34) 0.1
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Aspirin therapy in patients with diabetes and CKDtherapy reduced primary end points by
52% (HR 0.48 [95% CI 0.27–0.82]; P =
0.007) (Fig. 2). In the subgroups of male
or female, there was no signiﬁcant differ-
enceintheprimaryendpointbetweenthe
aspirin and nonaspirin group (data not
shown).
Safety
Incidence of the composite of gastroin-
testinal bleeding and cerebral bleeding
was very low and was similar between the
aspirin (three gastrointestinal bleeding
events and four cerebral bleeding events)
and nonaspirin (two gastrointestinal
bleeding events and four cerebral bleed-
ingevents)groupsinthegroupofpatients
with eGFR 60–89 mL/min/1.73 m
2.
CONCLUSIONS—In the present sub-
group analysis of JPAD, a prospective,
randomized, clinical trial of low-dose
aspirin versus nonaspirin groups for pri-
marypreventioninJapanesetype2patients
with diabetes, low-dose aspirin therapy
reduced the incidence of atherosclerotic
events in diabetic patients with eGFR 60–
89 mL/min/1.73 m
2,but not in those with




of patients with eGFR 60–89 mL/min/
1.73 m
2, there was no increase in serious
gastrointestinal and cerebral bleeding in
the aspirin group compared with the non-
aspirin group.
There has been rapidly growing in-
terest in the relation between renal dys-
function and atherosclerotic events in
general populations as well as patients at
risk for CV events. This is the ﬁrst sub-
analysis to clarify the efﬁcacy of aspirin in
reducing atherosclerotic risk in patients
stratiﬁed according to eGFR in patients
with diabetes. The current studyprovides
new information thateGFR may be useful
to identify candidates for aspirin therapy
among Japanese patients with diabetes.
We used the new three-variable Japanese
equation for GFR, which is more closely
correlated with the inulin clearance than
the Modiﬁcation of Diet in Renal Disease
equation in the Japanese population (14).
It is not clear, however, that eGFR-based
identiﬁcation can be applied to the Cau-
casian population, because GFR in the
Japanese population is lower than that
in Caucasians (15). Furthermore, some
previous studies in Western populations
had reported that Modiﬁcation of Diet in
Renal Disease equation or Cockcroft-
Gaultformulaunderestimated GFRinpa-
tients with diabetes, and that eGFR was
not a predictor of mortality (16,17). Fur-
ther studies are therefore necessary to
conﬁrm the usefulness of eGFR in this
strategy.
The progressive increase in CV risk
with worsening eGFR found in Japanese
patients with diabetes in this study is
consistent with previous data (8,18). It
has been hypothesized to be related to
factors associated with renal damage,
Figure 1—Percentage of primary end points by category of patients with eGFR of at least 90 mL/min/1.73 m
2 (A), 60–89 mL/min/1.73 m
2 (B), or
,60 mL/min/1.73 m2 (C).
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Saito and Associatesincluding anemia, oxidative stress, de-
rangements in calcium-phosphate ho-
meostasis, inﬂammation and conditions
promotingcoagulation(18).Thepossible
mechanism for the beneﬁcial effect of
low-dose aspirin therapy on the preven-
tion of atherosclerotic events in the sub-
group of patients with eGFR 60–89 mL/
min/1.73 m
2, is inhibition of thrombus
formation via blocking thromboxane-
dependent platelet activation. Recently,
aspirin also has been found to have pro-
tective effects on oxidative stress-induced
endothelial dysfunction in vivo, which
may be involved in the prevention of
atherosclerotic events (19,20). However,
it is not clear why low-dose aspirin ther-
apy could not prevent atherosclerotic
events in the subgroup of patients with
eGFR ,60 mL/min/1.73 m
2.G i v e nt h a t
aspirin in a daily dose of 100 mg or less is
associated with a higher incidence of aspi-
rin resistance in patients with diabetes or
renal dysfunction (21,22), one possible
explanation is that the dose of aspirin is
too low to inhibit platelet activation in
these patients. Another possible explana-
tion is that in patients with advanced kid-
ney disease, atherosclerotic events are
predominantly caused by factors such as
renal anemia, derangement of calcium-
phosphate homeostasis, and other un-
known renal-related factors that are not
inﬂuenced by aspirin.
During preparation of this manu-
script, the subanalysis of the Hyperten-
sionOptimalTreatment(HOT)studywas
published about the efﬁcacy of the low-
dose aspirin for primary prevention in
patientswithchronickidneydisease(23).
This study showed that low-dose aspirin
is beneﬁcial for preventing major CV dis-
ease in patients with eGFR ,45 mL/min/
1.73m
2(aspirin,11/264;placebo32/272;
HR 0.34 [95% CI 0.17–0.67]), and not in
those with eGFR $60 mL/min/1.73m
2
(aspirin, 233/7517; placebo, 252/7461;
0.91 [0.76–1.09]) (23). The result seems
inconsistent with our result; however,
the HOT study enrolled patients with
diastolic hypertension, and the rate of di-
abetic patients was only 8%. The under-
lying mechanisms were unclear, but the
difference in patients’ characteristics, es-
pecially coexisting with diabetes, might
affect the aspirin effect.
Along with progression of renal dam-
age in diabetes, GFR is normal or increases
to above the normal level in the early
period and then gradually decreases. The
proportion of patients with eGFR of at
least 90 mL/min/1.73 m
2 in the JPAD trial
was 21% of the total patients enrolled,
which was higher than the 13% preva-
lence for this eGFR category observed in
the general Japanese population (15). The
proportion with eGFR ,60 mL/min/1.73
m
2 in the JPAD trial was 25%, which was
also higher than the 16% prevalence in
the general population (15). This distri-
butional difference in eGFR is probably
explained by the characteristic progres-
sion pattern of diabetic renal damage. In
the current study, eGFR ,60 mL/min/
1.73 m
2—a usual cutoff value—was as-
sociated with increased atherosclerotic
risk, but in addition, eGFR 60–89 mL/
min/1.73 m
2 was also associated with
increased risk for any atherosclerotic
events.
Thisstudyhasafewlimitations.With
the nonblinded design, differential ascer-
tainment is possible; however, end point
classiﬁcationwasconductedbyablinded,
independentcommitteethatwasunaware
of the group assignments. Second, we
used the eGFR instead of direct measure-
ment of GFR using an exogenous marker,
such as inulin clearance. Equations for
estimating GFR have limited precision
compared with measured GFR. However,
for practical reasons, many large trials
have used eGFR calculated by the Mod-
iﬁcation of Diet in Renal Disease equation
or Cockcroft-Gault formula. Third, our
population enrolled only 20 patientswith
eGFR ,30 mL/min/1.73 m2 and no pa-
tientsreceivinghemodialysis,sowecould
not analyze the effect of aspirin in these
categories of patients. Finally, we did not
measure the rate of urinary albumin
excretion, a factor that may drive the
documented independent effect of the
baseline eGFR on CV outcomes.
Inconclusion,thecurrentstudydem-
onstrated that low-dose aspirin therapy
reduced the risk of atherosclerotic events
in type 2 diabetic patients with eGFR 60–
89 mL/min/1.73 m
2. The results suggest
that eGFR may be useful for risk stratiﬁ-
cation in the primary prevention strategy
withaspirin.However,astheseresultsare
from a post hoc subgroup analysis, they
should be viewed as hypothesis generat-
ing and should be investigated further in
additional studies.
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